8H7F

The crystal structure of human abl1 kinase domain in complex with abl1-B-EBA

Summary for 8H7F

• Entry DOI: 10.2210/pdb8h7f/pdb
• Descriptor: Tyrosine-protein kinase ABL1, 1-[6-(6-methoxyisoquinolin-7-yl)-1,3-benzothiazol-2-yl]-3-(2-oxidanylideneethyl)urea (3 entities in total)
• Functional Keywords: complex, inhibitor, lysine, transferase
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 2
• Total formula weight: 64910.04

Authors

Zhu, C.J.,Zhang, Z.M. (deposition date: 2022-10-20, release date: 2023-03-01, Last modification date: 2024-11-06)

Primary citation

Chen, P.,Tang, G.,Zhu, C.,Sun, J.,Wang, X.,Xiang, M.,Huang, H.,Wang, W.,Li, L.,Zhang, Z.M.,Gao, L.,Yao, S.Q.
2-Ethynylbenzaldehyde-Based, Lysine-Targeting Irreversible Covalent Inhibitors for Protein Kinases and Nonkinases.
J.Am.Chem.Soc., 2023

PubMed Abstract: Lysine-targeting irreversible covalent inhibitors have attracted growing interests in recent years, especially in the fields of kinase research. Despite encouraging progress, few chemistries are available to develop inhibitors that are exclusively lysine-targeting, selective, and cell-active. We report herein a 2-ethynylbenzaldehyde (EBA)-based, lysine-targeting strategy to generate potent and selective small-molecule inhibitors of ABL kinase by selectively targeting the conserved catalytic lysine in the enzyme. We showed the resulting compounds were cell-active, capable of covalently engaging endogenous ABL kinase in K562 cells with long-residence time and few off-targets. We further validated the generality of this strategy by developing EBA-based irreversible inhibitors against EGFR (a kinase) and Mcl-1 (a nonkinase) that covalently reacted with the catalytic and noncatalytic lysine within each target.

PubMed: 36774655
DOI: 10.1021/jacs.2c11595

Experimental method

X-RAY DIFFRACTION (2.4501342407 Å)